Back to top
more

Galectin Therapeutics (GALT)

(Delayed Data from NSDQ)

$3.45 USD

3.45
173,928

-0.05 (-1.43%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.47 +0.02 (0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Brokerage Reports

Research for GALT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galectin Therapeutics Inc. [GALT]

Reports for Purchase

Showing records 1 - 20 ( 105 total )

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 1

11/14/2023

Company Report

Pages: 8

3Q Recap: NAVIGATE Progresses Towards Interim Analysis in 4Q24; We See No Near-Term Financial Overhang; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 2

08/15/2023

Company Report

Pages: 8

2Q Recap; NAVIGATE Interim Analysis On Target For 4Q24; Seeking Options to Advance Belapectin in Oncology; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 3

05/17/2023

Company Report

Pages: 8

1Q Recap; NAVIGATE Phase 2b Interim Analysis in 4Q24 Represents Watershed Moment For Belapectin; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 4

03/31/2023

Company Report

Pages: 8

4Q Recap; NAVIGATE Phase 2b Interim Analysis On Target in 4Q24; Exploring Belapectin Oncology Opportunities; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 5

03/03/2023

Daily Note

Pages: 4

NAVIGATE Fully Enrolled; Top-Line Results of Phase 2b Interim Analysis in 4Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 6

12/02/2022

Daily Note

Pages: 3

NAVIGATE Phase 2b Full Enrollment On Target Around Year- End; Continue to Expect Mid-2024 Interim Readout; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 7

11/15/2022

Company Report

Pages: 8

3Q Recap; Phase 2b NAVIGATE Complete Enrollment Around Year-End; Interim Readout On Target for Mid-2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 8

10/07/2022

Daily Note

Pages: 3

NAVIGATE Continues As Planned After Second Positive DSMB Review; Complete Enrollment Around Year-End; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 9

08/16/2022

Company Report

Pages: 8

2Q Recap; We Continue to Expect NAVIGATE Phase 2b Data in Mid-2024; Cash Runway Through YE2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 10

07/26/2022

Daily Note

Pages: 3

New Line of Credit Extends Cash Runway Beyond NAVIGATE''s Phase 2b Interim Readout, Through 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 11

05/17/2022

Company Report

Pages: 8

1Q Recap; NAVIGATE Expands to Mexico and Latin America Sites; Interim Analysis Now in Mid-2024; Moderating PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 12

04/14/2022

Daily Note

Pages: 3

Belapectin Appears Safe and Well-Tolerated in First Positive DSMB Review of NAVIGATE

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 13

04/01/2022

Company Report

Pages: 8

4Q Recap: NAVIGATE Complete Enrollment on Target By End of 2Q22; Preparing Oncology Program IND; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 14

11/16/2021

Company Report

Pages: 9

3Q21 Recap; Details of Company-Sponsored Oncology Program Forthcoming in December Annual Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GALT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 16

09/22/2021

Daily Note

Pages: 3

New Convertible Debt Financing to Reach Key Value Inflection Point, As Long as NAVIGATE Enrollment Stays on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 17

08/17/2021

Company Report

Pages: 8

2Q21 Recap: 2H23 Interim Readout of NAVIGATE On Target, While Potential in Oncology Emerges; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 18

05/18/2021

Company Report

Pages: 8

1Q21 Recap; NAVIGATE Continues Enrolling Cirrhotic NASH Patients; Key Interim Readout in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 19

04/16/2021

Company Report

Pages: 9

Published Data Show Belapectin Enhances Cancer Immunotherapy Response

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 20

12/04/2020

Daily Note

Pages: 3

Galectin Running Full Steam Ahead With Belapectin in Three Clinical Trials; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party